Ganciclovir (sodium)

107910-75-8

277.21

H2O : 50 mg/mL (180.37 mM; Need ultrasonic); DMSO : 5 mg/mL (18.04 mM; Need ultrasonic)

Cell Cycle/DNA Damage; Anti-infection; Anti-infection; Anti-infection

Ganciclovir (BW 759) sodium, a nucleoside analogue and an orally active antiviral agent, shows activity against CMV. Ganciclovir sodium also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir sodium inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir sodium has an IC₅₀ of 5.2 uM for feline herpesvirus type-1 (FHV-1)^[1][2][3]. In Vitro: Ganciclovir sodium is an acyclic deoxyguanosine analog structurally similar to acyclovir but with superior activity against CMV. The median ganciclovir concentration required to inhibit viral replication by 50 percent is 2.15 mumol versus 72 mumol for acyclovir^[4].The primary mechanism of ganciclovir action against CMV is inhibition of the replication of viral DNA by ganciclovir-5'-triphosphate (ganciclovir-TP). This inhibition includes a selective and potent inhibition of the viral DNA polymerase. Ganciclovir sodium is metabolized to the triphosphate form by primarily three cellular enzymes: a deoxyguanosine kinase induced by CMV-infected cells; guanylate kinase; and phosphoglycerate kinase^[5]. In Vivo: Ganciclovir sodium (1-80 mg/kg; i.h.; daily for 5 days) delays MCMV-induced wasting syndrome and mortality^[6].